Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients

2019 ◽  
Vol 33 (12) ◽  
pp. 945-954 ◽  
Author(s):  
Nicolas Plouznikoff ◽  
Carlos Artigas ◽  
Spyridon Sideris ◽  
Nieves Martinez Chanza ◽  
Thierry Gil ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Pet Ct ◽  
Before And After ◽  
Psma Expression

11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel

2015 ◽  
Vol 43 (1) ◽  
pp. 84-91 ◽  
Author(s):  
Francesco Ceci ◽  
Paolo Castellucci ◽  
Tiziano Graziani ◽  
Riccardo Schiavina ◽  
Riccardo Renzi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Castration Resistant Prostate Cancer ◽  
Choline Pet ◽  
Castration Resistant ◽  
Pet Ct

scholarly journals Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Oncotarget ◽  
2014 ◽  
Vol 5 (23) ◽  
pp. 12448-12458 ◽  
Author(s):  
Ugo De Giorgi ◽  
Paola Caroli ◽  
Salvatore L. Burgio ◽  
Cecilia Menna ◽  
Vincenza Conteduca ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Outcome Prediction ◽  
Castration Resistant Prostate Cancer ◽  
Early Outcome ◽  
Castration Resistant ◽  
Pet Ct

scholarly journals Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Panagiotis J. Vlachostergios ◽  
Muhammad Junaid Niaz ◽  
Michael Sun ◽  
Seyed Ali Mosallaie ◽  
Charlene Thomas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Emission Computed Tomography ◽  
Prostate Specific Membrane Antigen ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Pet Ct ◽  
Specific Membrane ◽  
Psma Expression ◽  
Systemic Therapies

BackgroundProstate-specific membrane antigen (PSMA) imaging has been suggested as highly sensitive modality for detection of metastases in patients with biochemically recurrent or advanced prostate cancer (PCa). PSMA expression is associated with grade and stage and has a relationship with androgen receptor signaling. The aim of this study was to evaluate the prognostic utility of radiographic PSMA expression in men with metastatic castration-resistant prostate cancer (mCRPC).MethodsPatients with mCRPC and available baseline PSMA imaging were studied. Images by planar/single-photon emission computed tomography (SPECT) or positron emission tomography (PET)/CT were reviewed. Planar/SPECT images were scored semi-quantitatively and PET/CT scored quantitatively with comparison of tumor uptake to liver uptake on a scale of 0–4 in order to determine an imaging score (IS). The IS (high: 2–4 versus low: 0–1), subsequent receipt of life-prolonging systemic therapies (taxane chemotherapy, potent androgen receptor pathway inhibitors, sipuleucel-T, and radium-223), and the CALGB prognostic risk stratification of patients were analyzed according to overall survival (OS) in univariate and multivariate Cox’s proportional hazards models.ResultsHigh PSMA expression (IS 2–4) was found in 179 (75.21%) patients, and 59 (24.79%) patients had low PSMA uptake. The median OS of the entire cohort was 16.8 (95%CI: 14.9–19.3) months. Patients with a high IS had a significantly shorter OS of 15.8 (95%CI 13.0–18.1) months compared to those with low expression [22.7 (95%CI: 17.7–30.7) months, p = 0.002]. After accounting for use of life-prolonging therapies (p<0.001) and CALGB prognostic groups (p = 0.001), high PSMA IS emerged as an independent prognostic factor for OS [HR(95%CI): 1.7 (1.2–2.2); p = 0.003].ConclusionPresence of high radiographic PSMA expression on SPECT or PET/CT may portend a poor prognosis in patients with mCRPC treated with standard systemic therapies. This provides implications for therapeutic targeting of PSMA-avid disease as a means to improve outcomes.

scholarly journals Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer

2021 ◽  
Vol 22 (14) ◽  
pp. 7431
Author(s):  
Magdalena Staniszewska ◽  
Pedro Fragoso Costa ◽  
Matthias Eiber ◽  
Jasmin M. Klose ◽  
Jasmin Wosniack ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Flow Cytometry ◽  
Androgen Receptor ◽  
Xenograft Model ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Positron Emission ◽  
Pet Ct ◽  
Pre Treatment ◽  
Psma Expression

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) prolongs overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, men with low PSMA expression are excluded from RLT. We explored the effect of androgen receptor blockade with enzalutamide on PSMA expression. Assessment of PSMA and androgen receptor (AR) expression on the human PC cell lines 22Rv1, C4-2, and LNCaP by immunohistochemistry and flow cytometry revealed low (22Rv1) and high (C4-2 and LNCaP) PSMA expression, and high, comparable AR positivity. Treatment with enzalutamide increased PSMA levels in 22Rv1, C4-2, and LNCaP (2.2/2.3/2.6-fold, p = 0.0005/0.03/0.046) after one week compared to DMSO-treated controls as assessed by flow cytometry. NOD/Scid mice bearing 22Rv1 tumors were treated with enzalutamide for two weeks. Positron emission tomography/computed tomography (PET/CT) demonstrated higher tumor uptake of 68Ga-PSMA after enzalutamide treatment (p = 0.004). Similarly, a clinical case with low baseline PSMA avidity demonstrated increased uptake of 68Ga-PSMA after enzalutamide on PET/CT and post-therapeutic 177Lu-PSMA scintigraphy in a patient with mCRPC. Enzalutamide induced PSMA expression in the 22Rv1 xenograft model and in an mCRPC patient, both with low baseline tumoral PSMA levels. Therefore, enzalutamide pre-treatment might render patients with low PSMA expression eligible for 177Lu-PSMA RLT.

Sign in / Sign up

Export Citation Format

Share Document